Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology

Paul J McKiernan,2 Orla Cunninghamm,1,2 Catherine M Greenem,2 Sally-Ann Cryan1,31School of Pharmacy, Royal College of Surgeons in Ireland, 2Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland Education and Research Centre, Beaumont Hospital, 3Trinity Centre fo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	McKiernan PJ, Cunningham O, Greene CM, Cryan SA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3f93a17188f948a3965567322bd40b0d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3f93a17188f948a3965567322bd40b0d
record_format	dspace
spelling	oai:doaj.org-article:3f93a17188f948a3965567322bd40b0d2021-12-02T00:12:16ZTargeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology1176-91141178-2013https://doaj.org/article/3f93a17188f948a3965567322bd40b0d2013-10-01T00:00:00Zhttp://www.dovepress.com/targeting-mirna-based-medicines-to-cystic-fibrosis-airway-epithelial-c-a14667https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Paul J McKiernan,2 Orla Cunninghamm,1,2 Catherine M Greenem,2 Sally-Ann Cryan1,31School of Pharmacy, Royal College of Surgeons in Ireland, 2Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland Education and Research Centre, Beaumont Hospital, 3Trinity Centre for Bioengineering, Trinity College Dublin, Dublin, IrelandAbstract: Cystic fibrosis (CF) is an inherited disorder characterized by chronic airway inflammation. microRNAs (miRNAs) are endogenous small RNAs which act on messenger (m)RNA at a post transcriptional level, and there is a growing understanding that altered expression of miRNA is involved in the CF phenotype. Modulation of miRNA by replacement using miRNA mimics (premiRs) presents a new therapeutic paradigm for CF, but effective and safe methods of delivery to the CF epithelium are limiting clinical translation. Herein, polymeric nanoparticles are investigated for delivery of miRNA mimics into CF airway epithelial cells, using miR-126 as a proof-of-concept premiR cargo to determine efficiency. Two polymers, polyethyleneimine (PEI) and chitosan, were used to prepare miRNA nanomedicines, characterized for their size, surface (zeta) potential, and RNA complexation efficiency, and screened for delivery and cytotoxicity in CFBE41o- (human F508del cystic fibrosis transmembrane conductance regulator bronchial epithelial) cells using a novel high content analysis method. RNA extraction was carried out 24 hours post transfection, and miR-126 and TOM1 (target of Myb1) expression (a validated miR-126 target) was assessed. Manufacture was optimized to produce small nanoparticles that effectively complexed miRNA. Using high content analysis, PEI-based nanoparticles were more effective than chitosan-based nanoparticles in facilitating uptake of miRNA into CFBE41o- cells and this was confirmed in miR-126 assays. PEI-premiR-126 nanoparticles at low nitrogen/phosphate (N/P) ratios resulted in significant knockdown of TOM1 in CFBE41o- cells, with the most significant reduction of 66% in TOM1 expression elicited at an N/P ratio of 1:1 while chitosan-based miR-126 nanomedicines failed to facilitate statistically significant knockdown of TOM1 and both nanoparticles appeared relatively nontoxic. miRNA nanomedicine uptake can be qualitatively and quantitatively assessed rapidly by high content analysis and is highly polymer-dependent but, interestingly, there is not a direct correlation between the levels of miRNA uptake and the downstream gene knockdown. Polymeric nanoparticles can deliver premiRs effectively to CFBEs in order to modulate gene expression but must be tailored specifically for miRNA delivery.Keywords: miR-126, nanotechnology, cystic fibrosis, TOM1, high content analysis, inflammationMcKiernan PJCunningham OGreene CMCryan SADove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss Issue 1, Pp 3907-3915 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 McKiernan PJ Cunningham O Greene CM Cryan SA Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
description	Paul J McKiernan,2 Orla Cunninghamm,1,2 Catherine M Greenem,2 Sally-Ann Cryan1,31School of Pharmacy, Royal College of Surgeons in Ireland, 2Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland Education and Research Centre, Beaumont Hospital, 3Trinity Centre for Bioengineering, Trinity College Dublin, Dublin, IrelandAbstract: Cystic fibrosis (CF) is an inherited disorder characterized by chronic airway inflammation. microRNAs (miRNAs) are endogenous small RNAs which act on messenger (m)RNA at a post transcriptional level, and there is a growing understanding that altered expression of miRNA is involved in the CF phenotype. Modulation of miRNA by replacement using miRNA mimics (premiRs) presents a new therapeutic paradigm for CF, but effective and safe methods of delivery to the CF epithelium are limiting clinical translation. Herein, polymeric nanoparticles are investigated for delivery of miRNA mimics into CF airway epithelial cells, using miR-126 as a proof-of-concept premiR cargo to determine efficiency. Two polymers, polyethyleneimine (PEI) and chitosan, were used to prepare miRNA nanomedicines, characterized for their size, surface (zeta) potential, and RNA complexation efficiency, and screened for delivery and cytotoxicity in CFBE41o- (human F508del cystic fibrosis transmembrane conductance regulator bronchial epithelial) cells using a novel high content analysis method. RNA extraction was carried out 24 hours post transfection, and miR-126 and TOM1 (target of Myb1) expression (a validated miR-126 target) was assessed. Manufacture was optimized to produce small nanoparticles that effectively complexed miRNA. Using high content analysis, PEI-based nanoparticles were more effective than chitosan-based nanoparticles in facilitating uptake of miRNA into CFBE41o- cells and this was confirmed in miR-126 assays. PEI-premiR-126 nanoparticles at low nitrogen/phosphate (N/P) ratios resulted in significant knockdown of TOM1 in CFBE41o- cells, with the most significant reduction of 66% in TOM1 expression elicited at an N/P ratio of 1:1 while chitosan-based miR-126 nanomedicines failed to facilitate statistically significant knockdown of TOM1 and both nanoparticles appeared relatively nontoxic. miRNA nanomedicine uptake can be qualitatively and quantitatively assessed rapidly by high content analysis and is highly polymer-dependent but, interestingly, there is not a direct correlation between the levels of miRNA uptake and the downstream gene knockdown. Polymeric nanoparticles can deliver premiRs effectively to CFBEs in order to modulate gene expression but must be tailored specifically for miRNA delivery.Keywords: miR-126, nanotechnology, cystic fibrosis, TOM1, high content analysis, inflammation
format	article
author	McKiernan PJ Cunningham O Greene CM Cryan SA
author_facet	McKiernan PJ Cunningham O Greene CM Cryan SA
author_sort	McKiernan PJ
title	Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
title_short	Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
title_full	Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
title_fullStr	Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
title_full_unstemmed	Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
title_sort	targeting mirna-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/3f93a17188f948a3965567322bd40b0d
work_keys_str_mv	AT mckiernanpj targetingmirnabasedmedicinestocysticfibrosisairwayepithelialcellsusingnanotechnology AT cunninghamo targetingmirnabasedmedicinestocysticfibrosisairwayepithelialcellsusingnanotechnology AT greenecm targetingmirnabasedmedicinestocysticfibrosisairwayepithelialcellsusingnanotechnology AT cryansa targetingmirnabasedmedicinestocysticfibrosisairwayepithelialcellsusingnanotechnology
_version_	1718403858943705088

Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology

Ejemplares similares